Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$29M | — | — | 471.7% | -420.4% | -$15M | — | $269830 |
| 2024 | — | -$9M | — | — | 271.9% | -160.4% | — | — | $6M |
| 2023 | — | -$8M | — | — | 32.4% | -976.3% | — | — | $38982 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$9M | — | — | 72.5% | -87.2% | — | — | $205035 |
| Mar '26 | — | -$10M | — | — | 96.1% | -142.4% | — | — | $917552 |
| Dec '25 | — | -$13M | — | — | 220.8% | -196.8% | -$4M | — | $269830 |
| Sep '25 | — | -$7M | — | — | -189.1% | -76.8% | -$5M | — | $2M |
| Jun '25 | — | -$5M | — | — | -91.8% | -44.0% | -$3M | — | $3M |
| Mar '25 | — | -$4M | — | — | 92.6% | -91.2% | -$4M | — | $3M |
| Dec '24 | — | -$3M | — | — | 91.6% | -54.0% | — | — | $6M |
| Sep '24 | — | -$3M | — | — | 406.6% | -145.4% | — | — | $2M |
| Jun '24 | — | -$2M | — | — | 5.8% | -116.0% | — | — | $94925 |
| Mar '24 | — | -$1M | — | — | 5.7% | -139.1% | — | — | $100231 |
| Dec '23 | — | -$1M | — | — | 6.1% | -183.5% | — | — | $38982 |
| Sep '23 | — | -$2M | — | — | 8.8% | — | — | — | $16059 |
| Jun '23 | — | -$3M | — | — | 11.8% | — | — | — | $49222 |
| Mar '23 | — | -$2M | — | — | 9.9% | — | — | — | $355214 |
See the revenue and net-income charts above for OS Therapies Inc's multi-year trend.
As of FY2025, OS Therapies Inc reported — of total debt against $269830 of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.